Sida Zhao
Shanghai, 200000, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Molecular characterization and improved risk stratification of myelodysplastic syndromes with bone marrow fibrosis through integration of TP53 and MPL mutations.
Journal: Discover oncology
Published: November 11, 2025
Carfilzomib-induced sinus bradycardia: A case report and literature review.
Journal: SAGE open medical case reports
Published: August 18, 2025
Enhanced FOXO1 expression as a predictor of decitabine response and prolonged survival in high-risk myelodysplastic syndrome.
Journal: Hematology (Amsterdam, Netherlands)
Published: May 27, 2025
Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes.
Journal: European journal of pharmacology
Published: June 24, 2024
Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes.
Journal: Leukemia & lymphoma
Published: October 22, 2023
S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression.
Journal: Acta biochimica et biophysica Sinica
Published: February 22, 2023
Decreased FOXO1 Expression Is Correlated with Poor Prognosis in Myelodysplastic Syndromes.
Journal: Current oncology (Toronto, Ont.)
Published: August 22, 2022
IGF‑IR promotes clonal cell proliferation in myelodysplastic syndromes via inhibition of the MAPK pathway.
Journal: Oncology reports
Published: September 11, 2019
Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells.
Journal: Cell death & disease
Published: December 07, 2017
Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway.
Journal: Cell death & disease
Published: November 02, 2017
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway.
Journal: Oncotarget
Published: February 14, 2017
Last Updated: 09/26/2026